These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26492443)

  • 1. Factor V Leiden.
    Van Cott EM; Khor B; Zehnder JL
    Am J Hematol; 2016 Jan; 91(1):46-9. PubMed ID: 26492443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM; Thom JY; Ivey JG; Baker RI
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
    Houghton DE; Sud S; Moll S; Rollins-Raval MA
    Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of factor V Leiden in a population of patients with congenital heart disease.
    Ong BC; Zimmerman AA; Zappulla DC; Neufeld EJ; Burrows FA
    Can J Anaesth; 1998 Dec; 45(12):1176-80. PubMed ID: 10051935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.
    Male C; Mitchell L; Julian J; Vegh P; Joshua P; Adams M; David M; Andrew ME
    Blood; 2001 Feb; 97(4):844-9. PubMed ID: 11159506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APC resistance: biological basis and acquired influences.
    Castoldi E; Rosing J
    J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
    Gessoni G; Valverde S; Gessoni F; Valle R
    Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
    [No Abstract]   [Full Text] [Related]  

  • 14. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
    Van Cott EM; Soderberg BL; Laposata M
    Arch Pathol Lab Med; 2002 May; 126(5):577-82. PubMed ID: 11958664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis.
    Uthman I; Khalil I; Sawaya R; Taher A
    Clin Rheumatol; 2004 Aug; 23(4):362-3. PubMed ID: 15293102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Leiden mutation of coagulation factor V in Hungarian SLE patients.
    Regéczy N; Lakos G; Balogh I; Ajzner E; Kiss E; Szegedi G
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):41-5. PubMed ID: 10726048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor V Leiden: a disorder of factor V anticoagulant function.
    Castoldi E; Rosing J
    Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Caruso P; Gessoni F; Valle R
    Blood Transfus; 2017 Oct; 15(6):562-567. PubMed ID: 28287382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in laboratory testing for thrombophilia.
    Johnson NV; Khor B; Van Cott EM
    Am J Hematol; 2012 May; 87 Suppl 1():S108-12. PubMed ID: 22473489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation (g2172-->c) in the factor V gene in a Chinese family with hereditary activated protein C resistance.
    Cai H; Hua B; Fan L; Wang Q; Wang S; Zhao Y
    Thromb Res; 2010 Jun; 125(6):545-8. PubMed ID: 20304467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.